Serum cytokine variations among inpatients with major depression, bipolar disorder, and schizophrenia versus healthy controls: a prospective 'true-to-life' study.

IF 3.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY Therapeutic Advances in Psychopharmacology Pub Date : 2023-01-01 DOI:10.1177/20451253221135463
Antonio Augusto Schmitt Junior, Lucas Primo de Carvalho Alves, Barbara Larissa Padilha, Neusa Sica da Rocha
{"title":"Serum cytokine variations among inpatients with major depression, bipolar disorder, and schizophrenia <i>versus</i> healthy controls: a prospective 'true-to-life' study.","authors":"Antonio Augusto Schmitt Junior,&nbsp;Lucas Primo de Carvalho Alves,&nbsp;Barbara Larissa Padilha,&nbsp;Neusa Sica da Rocha","doi":"10.1177/20451253221135463","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is increasing evidence of the association between chronic low-grade inflammation and severe mental illness (SMI). The objective of our study was to assess serum cytokine levels (SCLs) at admission and discharge in a true-to-life-setting population of inpatients with major depression (MD), bipolar disorder (BD), and schizophrenia (Sz), as well as of healthy controls.</p><p><strong>Methods: </strong>We considered MD, BD, and Sz to be SMIs. We evaluated 206 inpatients [MD, <i>N</i> = 92; BD, <i>N</i> = 26; mania (Ma), <i>N</i> = 44; Sz, <i>N</i> = 44). Generalized estimating equations were used to analyze variations in SCL [interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukin (IL)-2, IL-4, IL-6, IL-10, and IL-17] at hospital admission and discharge. Results of 100 healthy controls were compared with those of SMI patients at both time points. We evaluated patients' improvement during in-hospital treatment in terms of general psychiatric symptoms, global clinical impression, functionality, and manic and depressive symptoms with validated scales.</p><p><strong>Results: </strong>In all, 68.9% of patients completed the study. Overall, SMI inpatients had higher SCL when compared with controls regardless of diagnosis. There was a significant decrease in Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression-Severity Scale (CGI-S) scores, and an increase in Global Assessment of Functioning (GAF) scores for all disorders evaluated (<i>p</i> < 0.001), as well as a significant decrease in HDRS-17 scores among MD inpatients (<i>p</i> < 0.001) and in YMRS scores among Ma inpatients (<i>p</i> < 0.001). IL-2 and IL-6 levels decreased significantly between admission and discharge only among MD inpatients (<i>p</i> = 0.002 and <i>p</i> = 0.03, respectively). We found no further statistically significant changes in SCL among the remaining disorders (BD, Ma, and Sz). There was no significant decrease in IFN-γ (<i>p</i> = 0.64), TNF-α (<i>p</i> = 0.87), IL-4 (<i>p</i> = 0.21), IL-10 (<i>p</i> = 0.88), and IL-17 (<i>p</i> = 0.71) levels in any of the evaluated diagnoses.</p><p><strong>Conclusion: </strong>MD inpatients had a decrease in IL-2 and IL-6 levels during hospitalization, which was accompanied by clinical improvement. No associations were found for the remaining SMIs (BD, Ma, and Sz).</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/46/c5/10.1177_20451253221135463.PMC9940172.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20451253221135463","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: There is increasing evidence of the association between chronic low-grade inflammation and severe mental illness (SMI). The objective of our study was to assess serum cytokine levels (SCLs) at admission and discharge in a true-to-life-setting population of inpatients with major depression (MD), bipolar disorder (BD), and schizophrenia (Sz), as well as of healthy controls.

Methods: We considered MD, BD, and Sz to be SMIs. We evaluated 206 inpatients [MD, N = 92; BD, N = 26; mania (Ma), N = 44; Sz, N = 44). Generalized estimating equations were used to analyze variations in SCL [interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukin (IL)-2, IL-4, IL-6, IL-10, and IL-17] at hospital admission and discharge. Results of 100 healthy controls were compared with those of SMI patients at both time points. We evaluated patients' improvement during in-hospital treatment in terms of general psychiatric symptoms, global clinical impression, functionality, and manic and depressive symptoms with validated scales.

Results: In all, 68.9% of patients completed the study. Overall, SMI inpatients had higher SCL when compared with controls regardless of diagnosis. There was a significant decrease in Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression-Severity Scale (CGI-S) scores, and an increase in Global Assessment of Functioning (GAF) scores for all disorders evaluated (p < 0.001), as well as a significant decrease in HDRS-17 scores among MD inpatients (p < 0.001) and in YMRS scores among Ma inpatients (p < 0.001). IL-2 and IL-6 levels decreased significantly between admission and discharge only among MD inpatients (p = 0.002 and p = 0.03, respectively). We found no further statistically significant changes in SCL among the remaining disorders (BD, Ma, and Sz). There was no significant decrease in IFN-γ (p = 0.64), TNF-α (p = 0.87), IL-4 (p = 0.21), IL-10 (p = 0.88), and IL-17 (p = 0.71) levels in any of the evaluated diagnoses.

Conclusion: MD inpatients had a decrease in IL-2 and IL-6 levels during hospitalization, which was accompanied by clinical improvement. No associations were found for the remaining SMIs (BD, Ma, and Sz).

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
重度抑郁症、双相情感障碍和精神分裂症住院患者血清细胞因子变化与健康对照:一项前瞻性“真实生活”研究
背景:越来越多的证据表明慢性低度炎症与严重精神疾病(SMI)之间存在关联。本研究的目的是评估重度抑郁症(MD)、双相情感障碍(BD)和精神分裂症(Sz)住院患者以及健康对照者入院和出院时的血清细胞因子水平(SCLs)。方法:我们认为MD、BD和Sz是SMIs。我们评估了206例住院患者[MD, N = 92;Bd, n = 26;躁狂(Ma), N = 44;Sz, N = 44)。采用广义估计方程分析住院和出院时SCL[干扰素γ (IFN-γ)、肿瘤坏死因子α (TNF-α)、白细胞介素(IL)-2、IL-4、IL-6、IL-10和IL-17]的变化。将100名健康对照者与重度精神分裂症患者在两个时间点的结果进行比较。我们用有效的量表评估患者在住院治疗期间的一般精神症状、整体临床印象、功能、躁狂和抑郁症状的改善。结果:68.9%的患者完成了研究。总体而言,与对照组相比,无论诊断如何,重度精神分裂症住院患者的SCL均较高。简短精神病学评定量表(BPRS)和临床总体印象严重程度量表(CGI-S)得分显著下降,所有被评估疾病的总体功能评估(GAF)得分显著上升(p p p分别= 0.002和p = 0.03)。我们发现在其余疾病(BD、Ma和Sz)中,SCL没有进一步的统计学显著变化。在任何评估的诊断中,IFN-γ (p = 0.64)、TNF-α (p = 0.87)、IL-4 (p = 0.21)、IL-10 (p = 0.88)和IL-17 (p = 0.71)水平均无显著降低。结论:MD住院患者在住院期间IL-2、IL-6水平下降,并伴有临床改善。其余的smi (BD、Ma和Sz)未发现关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.90
自引率
2.40%
发文量
35
审稿时长
10 weeks
期刊介绍: Therapeutic Advances in Psychopharmacology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in psychopharmacology, providing a forum in print and online for publishing the highest quality articles in this area.
期刊最新文献
Use of an injection of aripiprazole given once every 2 months (Abilify Asimtufii®) in people with bipolar I disorder: a Plain Language Summary of Publication. Exploring the clinical factors affecting lithium dose and plasma level and the effect of brand. Low-frequency repetitive transcranial magnetic stimulation for the treatment of post-traumatic stress disorder and its comparison with high-frequency stimulation: a systematic review and meta-analysis. Risperidone ISM®: review and update of its usefulness in all phases of schizophrenia. Incorporation of a specialist mental health clinical pharmacist within a primary care network: patient referrals, prescribing decisions, and clinical outcomes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1